Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice
Kuo-Tung Hung,Shih-Cheng Yang,Cheng-Kun Wu,Hsing-Ming Wang,Chih-Chien Yao,Chih-Ming Liang,Wei-Chen Tai,Keng-Liang Wu,Yuan-Hung Kuo,Chen-Hsiang Lee,Seng-Kee Chuah
DOI: https://doi.org/10.2147/IDR.S304711
2021-03-25
Infection and Drug Resistance
Abstract:Kuo-Tung Hung, 1 Shih-Cheng Yang, 1 Cheng-Kun Wu, 1, 2 Hsing-Ming Wang, 1 Chih-Chien Yao, 1 Chih-Ming Liang, 1, 2 Wei-Chen Tai, 1, 2 Keng-Liang Wu, 1, 2 Yuan-Hung Kuo, 1, 2 Chen-Hsiang Lee, 2, 3 Seng-Kee Chuah 1, 2 1 Division of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 2 Chang Gung University, College of Medicine, Taoyuan, Taiwan; 3 Division of Infectious Disease, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan Correspondence: Seng-Kee Chuah; Chih-Ming Liang Division of Hepatogastroenterology, Chang Gung Memorial Hospital, 123, Ta-Pei Road, Niao-Sung Hsiang, Kaohsiung, 833, Taiwan Tel + 886-7-7317123 ext. 8301 Fax + 886-7-7322402 Email chuahsk@seed.net.tw; gimy54861439@gmail.com Purpose: Non-bismuth concomitant quadruple therapy is commonly administered in Taiwan, achieving an acceptable efficacy as a first-line anti -Helicobacter pylori treatment. This study compared the eradication rates between esomeprazole- and lansoprazole-based non-bismuth concomitant quadruple therapy for first-line anti- H. pylori treatment. Patients and Methods: This study included 206 H. pylori -infected naïve patients between July 2016 and February 2019. The patients were prescribed with either a 7-day non-bismuth containing quadruple therapy (esomeprazole, 40 mg twice daily; amoxicillin, 1 g twice daily; and metronidazole, 500 mg twice daily; and clarithromycin, 500 mg twice daily for 7 days [EACM group]; lansoprazole, 30 mg twice daily; amoxicillin, 1 g twice daily; metronidazole, 500 mg twice daily; and clarithromycin, 500 mg twice daily [LACM group]). Then, the patients were asked to perform urea breath tests 8 weeks later. Results: The eradication rates in the EACM group were 86.1% (95% confidence interval [CI], 77.8%– 92.2%) and 90.6% (95% CI, 82.9%– 95.6%) in the intention-to-treat (ITT) and the per-protocol (PP) analyses, respectively. Moreover, the eradication rates in the LACM group were 90.1% (95% CI, 82.6%– 95.2%) and 92.6% (95% CI, 85.5%– 96.9%) in the ITT and the PP analyses, respectively. Consequently, the LACM group exhibited more diarrhea patients than the EACM group (7.1% versus 1.0%, p = 0.029), but all symptoms were mild. Univariate analysis in this study showed that metronidazole-resistant strains were the clinical factor affecting the eradications (95.3% versus 78.9%, p = 0.044). Moreover, a trend was observed in dual clarithromycin- and metronidazole-resistant strains (91.5% versus 66.7%, p = 0.155). Conclusion: The eradication rates between esomeprazole and lansoprazole-based non-bismuth concomitant quadruple therapy for first-line H. pylori treatment were similar in this study. Both could achieve a > 90% report card in the PP analysis. Keywords: Helicobacter pylori , esomeprazole, lansoprazole, concomitant therapy, antibiotic resistance
pharmacology & pharmacy,infectious diseases